Skip to main content

Table 4 Clinical data in analyzed patients

From: Estimated influence of a novel biocompatible dialysis membrane on vascular events in dialysis patients with diabetic nephropathy: a prospective randomized controlled pilot study

 

Pre

1 year

2 years

3 years

Number of patients

 NV group

15

15

15

15

 PS group

15

15

15

15

Pentosidine (μg/mL)

 NV group

0.45 ± 0.26

0.52 ± 0.25

0.51 ± 0.27

0.60 ± 0.39

 PS group

0.41 ± 0.19

0.62 ± 0.19

0.57 ± 0.15

0.66 ± 0.16

ELAM-1 (ng/mL)

 NV group

43.4 ± 19.1

42.1 ± 18.0

47.3 ± 18.5

48.8 ± 17.6

 PS group

37.8 ± 17.8

43.2 ± 21.9

38.7 ± 20.3

39.6 ± 18.3

LDL-C (mg/dL)

NV group

83 ± 25

83 ± 25

88 ± 31

87 ± 30

PS group

77 ± 19

76 ± 22

75 ± 20

78 ± 23

HDL-C (mg/dL)

 NV group

49 ± 14

47 ± 14

46 ± 14

47 ± 15

 PS group

47 ± 24

47 ± 24

47 ± 24

78 ± 23

ABI (right)

 NV group

1.04 ± 0.14

0.98 ± 0.15

1.00 ± 0.17

0.92 ± 0.16

 PS group

1.00 ± 0.26

0.95 ± 0.21

0.95 ± 0.22

0.91 ± 0.24

ABI (left)

 NV group

1.00 ± 0.12

0.96 ± 0.12

0.98 ± 0.12

0.92 ± 0.16

 PS group

1.03 ± 0.11

1.00 ± 0.13

0.99 ± 0.15

0.98 ± 0.17

CAVI (right)

 NV group

8.9 ± 1.1

9.2 ± 1.4

9.5 ± 1.3

9.5 ± 1.4

 PS group

9.1 ± 1.5

9.4 ± 1.8

9.0 ± 1.4

9.1 ± 1.4

CAVI (left)

 NV group

8.9 ± 1.3

9.3 ± 1.5

9.3 ± 1.2

9.5 ± 1.0

 PS group

8.2 ± 0.8

8.7 ± 1.0

8.7 ± 1.4

8.9 ± 0.7

Serum albumin (g/dL)

 NV group

4.0 ± 0.6

4.0 ± 0.2

3.9 ± 0.3

3.9 ± 0.2

 PS group

4.0 ± 0.2

3.9 ± 0.3

3.8 ± 0.4

3.8 ± 0.6

Body weight (kg)

 NV group

64.7 ± 11.1

63.8 ± 11.8

64.1 ± 11.9

62.9 ± 11.3

 PS group

61.8 ± 10.5

62.2 ± 11.5

61.8 ± 11.2

61.4 ± 11.0

BMI (kg/m2)

 NV group

24.4 ± 3.6

24.3 ± 4.0

24.5 ± 4.0

24.1 ± 3.8

 PS group

23.6 ± 3.1

24.0 ± 2.9

23.8 ± 2.7

23.7 ± 2.7

GNRI

 NV group

100.0 ± 8/9

100.2 ± 3.9

99.6 ± 5.2

99.0 ± 4.0

 PS group

99.7 ± 4.4

98.8 ± 5.1

97.2 ± 6.5

96.9 ± 9.5

Hemoglobin (g/dL)

 NV group

10.6 ± 0.6

10.5 ± 0.4*

10.5 ± 0.7

10.6 ± 0.8

 PS group

10.3 ± 0.4

10.2 ± 0.5

10.4 ± 0.7

10.2 ± 0.7

WBC (cells/μL)

 NV group

6154 ± 1293

6181 ± 1151

6856 ± 2047

6726 ± 2513

 PS group

5791 ± 711

6147 ± 1175

6078 ± 1016

6017 ± 882

Platelet (× 104 cells/μL)

 NV group

20.7 ± 8.9

21.7 ± 8.0

21.4 ± 8.3

19.9 ± 11.1

 PS group

18.8 ± 6.4

18.3 ± 5.8

18.5 ± 5.7

17.8 ± 5.1

  1. Results are presented as the mean ± standard deviation
  2. NV TORAYLIGHT NV, PS polysulfone, ELAM endothelial leukocyte adhesion molecule-1, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ABI ankle brachial index, CAVI cardio-ankle vascular index, BMI body mass index, GNRI geriatric nutritional risk index, WBC white blood cell
  3. *P < 0.05 vs. PS group
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us